Physiological and Pathophysiological Regulation of the Ryanodine Receptor in Skeletal Muscle
Total Page:16
File Type:pdf, Size:1020Kb
Physiological and pathophysiological regulation of the ryanodine receptor in skeletal muscle Alisa Umanskaya Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2015 © 2015 Alisa Umanskaya All rights reserved Abstract Physiological and pathophysiological regulation of ryanodine receptor in skeletal muscle Alisa Umanskaya Ryanodine receptor calcium release channels are essential for skeletal muscle contraction, as they mediate the release of calcium ions from intracellular stores into the cytosol. The data presented in this dissertation demonstrate the evolutionarily conserved mechanisms of skeletal muscle ryanodine receptor regulation in the physiological and pathophysiological states. Adrenergic stimulation causes increased skeletal muscle force, however, despite the well- established role of this physiological response, the molecular mechanism is not known. Here we present a mechanism whereby phosphorylation of a single amino acid on the ryanodine receptor is a key signal in the physiological stress-induced inotropic response in mouse skeletal muscle. Therefore acute post-translational modifications of ryanodine receptor channels are important for healthy muscle contraction. Conversely, chronic stress-induced post-translational modifications result in poorly functioning murine ryanodine receptor channels that contribute to skeletal muscle dysfunction in age- dependent skeletal muscle weakness and Muscular Dystrophies. Finally, we present data that demonstrates striking evolutionary conservation in ryanodine receptor regulation in the physiological and pathophysiological states between mice and C. elegans. This work has broad implications for understanding the underlying mechanisms of skeletal muscle contraction and important disorders that affect human health. Furthermore, this works presents ryanodine receptor channels as a viable therapeutic target for age-related skeletal muscle weakness, Muscular Dystrophies, and also implicates C. elegans as a potential model system in which to test future therapeutic targets. Table of Contents List of Figures……………………………………………………………………………..ii Chapter 1: Introduction…………………………………………………………………… 1 v Mammalian excitation-contraction coupling……………………………………... 1 v Ryanodine receptors……………………………………………………………… 6 v Ryanodine receptor regulation by post-translational modifications and regulatory proteins………………………………………………………………....………... 11 v Ryanodine receptor redox sensing………………………….…………………… 16 v Ryanodine receptor-related skeletal muscle pathophysiology………….……….. 21 v Excitation-contraction coupling in C. elegans……….…………….……………. 23 v Redox balance/imbalance in aging C. elegans………………………….………..28 v Rationale and aims………………………………………………………………. 30 Chapter 2: Post-translational modification of the ryanodine receptor type 1 underlies skeletal muscle weakness in the physiological and pathophysiological state…………… 38 v Phosphorylation of the ryanodine receptor by protein kinase A is a molecular mechanism underlying fast twitch skeletal muscle inotropy……………………. 38 v Post-translational modifications of the ryanodine receptor mechanistically underlie skeletal muscle weakness in Limb-girdle muscular dystrophy...……… 45 Chapter 3: Skeletal Muscle Aging: An acquired form of Muscular Dystrophy...………. 53 v Ryanodine receptor oxidation causes muscle weakness in aging. ...……………. 53 v Genetically enhancing mitochondrial anti-oxidant activity improves muscle function in aging.…………………………….......……………………………… 77 Chapter 4: C. elegans: A model for the physiological study of muscle function in aging…………………………………………………………………………………… 104 v The role of the UNC-68/intracellular calcium release channel in age- dependent loss of muscle function in C. elegans………………………. 104 Discussion………………………….......………………………………………………. 120 References………………………………………………………………………………132 i List of figures Figure 1: Cardiac vs. skeletal muscle E-C coupling.……………………………….…… 33 Figure 2: Physiological vs. pathophysiological skeletal muscle E-C coupling…………. 34 Figure 3: Oxidative systems in mammalian skeletal muscle and C. elegans…………… 35 Figure 4: Schematic representation of the dystrophin glycoprotein complex (DGC)…... 36 Figure 5: Sequence identity between mammalian and C. elegans ryanodine receptors and immunophillins...…………………………………….……………………..………….... 37 Figure 6: β-adrenergic pathway………………………………….……………….……... 53 Figure 7: RyR1-S2844A muscle exhibits similar force to WT muscle…………………. 54 Figure 8: β-adrenergic inotropy in skeletal muscle is dependent on phosphorylation of serine 2844 in RyR1.………………………………….……………….…….......………. 55 Figure 9: Blocking phosphorylation of RyR1 at S2844 inhibits the β-adrenergic effect on Ca2+ transients in FDB muscle fibers. ……….…….……….…….……….…….………. 56 Figure 10: Abolished phosphorylation of RyR1 following β-adrenergic stimulation and reduced in vivo force production in S2844A mice..…….……….…….………………… 57 Figure 11: RyR1 in β-sarcoglycan deficient muscle is cysteine-nitrosylated, oxidized and depleted of calstabin1.…….……….…….…………….……….…….…………………. 58 Figure 12: β-sarcoglycan deficient muscle displays defective SR Ca2+ release that is restored by S107 treatment..…….……….…….……….…….……………….…..…….. 59 Figure 13: S107 treatment increases muscle force in β-sarcoglycan deficient mice……..60 Figure 14: S107 treatment increases voluntary exercise in β-sarcoglycan deficient mice..…….…………….………………….………………….………………….……….61 Figure 15: EDL muscles from β-sarcoglycan deficient mice exhibit abnormal mitochondrial morphology.……………....………………….…………………………...62 Figure 16: Impaired force production and reduced SR Ca2+ release in EDL muscle from aged mice.……………....………………….…………….………………………... 90 Figure 17: RyR1 from aged muscle is cysteine-nitrosylated, oxidized and depleted of calstabin1..………………....………………….…………....………………….………... 91 ii Figure 18: Pharmacological dissociation of RyR1 and calstabin1 causes increased mitochondrial Ca2+……....………………….…………....………………….…………... 92 Figure 19: Pharmacological dissociation of RyR1 and calstabin1 causes reduced mitochondrial membrane potential.……....………………….……….……….………… 93 Figure 20: Pharmacological dissociation of RyR1 and calstabin1 causes increased mitochondrial ROS and RNS production.….……….…………….……….……………. 94 Figure 21: Improved exercise capacity and muscle specific force following S107 treatment of aged mice…………………..….……….…………….……….……………. 95 Figure 22: Increased SR Ca2+ release following S107 treatment of aged mice..………... 96 Figure 23: Model of RyR1-mediated SR Ca2+ leak and mitochondrial dysfunction in aging skeletal muscle.……………..….……….……………..……………..….………... 97 Figure 24: Improved exercise capacity in aged MCat mice.……………..……………... 98 Figure 25: Preserved skeletal muscle function in aged MCat mice.…..……..…………. 99 Figure 26: Improved tetanic Ca2+ in skeletal muscle from aged MCat mice…..………. 100 Figure 27: SERCA1 activity in MCat mice is similar to WT..……………..………….. 101 Figure 28: Reduced SR Ca2+ spark activity and increased SR Ca2+ load in muscle from aged MCat mice...……………..…………..………..……………..………..………….. 101 Figure 29: Skeletal muscle RyR1 isolated from aged MCat mice is biochemically remodeled and exhibits reduced single-channel open probability (Po)…………………102 Figure 30: UNC-68 is comprised of a macromolecular complex……………………… 113 Figure 31: Age-dependent reduction in Ca2+ transients is accelerated in fkb-2 relative to WT………………………………………………………………………………………114 Figure 32: Age-dependent UNC-68 remodeling is accelerated in fkb-2 relative to WT………………………………………………………………………………………115 Figure 33: Depleting FKB-2 from UNC-68 causes UNC-68 oxidation.…………….…116 Figure 34: FKB-2 depletion from UNC-68 causes defective Ca2+ handling………...…117 Figure 35: UNC-68 oxidation causes defective Ca2+ handling…………….………...…118 iii Figure 36: Treating aged nematodes with the RyR-stabilizing drug, S107, increases body wall muscle Ca2+ transients in aged C. elegans.…………….……….........................…119 Supplementary Figure 1: Confirmation that FKB-2 is part of the UNC-68 macromolecular complex…………………………………………………..........…………...121 iv Acknowledgements I consider myself lucky to have found my way into Dr. Marks’ laboratory and to have had the opportunity to be mentored by him. His passion for scientific inquiry is infectious and I hope to embody that enthusiasm and wisdom in my future endeavors. Furthermore, I would like to thank my lab mates, past and present, for supporting me technically and mentally with openness and humor throughout my years in the Marks laboratory. It has been a true pleasure to learn from and work with so many true experts and I am truly thankful for all of the guidance and help that they have provided throughout the years. I would especially like to thank Steve Reiken, who in his own way, takes care of the laboratory and the people in it. The post-doctoral scientists and graduate students in the laboratory of Dr. Martin Chalfie were also instrumental in teaching me the basic methodologies involved in the C. elegans component of my dissertation. Dr. Irini Topalidou, in addition to being a wonderful scientific resource throughout my training, has also become a dear friend. I would like to thank the members of my committee, Drs. Henry Colecraft, Iva Greenwald, Monica Driscoll, and Alain Lacampagne. Dr. Colecraft was the Director of Graduate Studies throughout most of my time in the Physiology and Cellular Biophysics Department and he has been a kind source of encouragement. Both, Drs. Greenwald and Driscoll